Morgan Stanley Celcuity Inc. Transaction History

Morgan Stanley

$1.59 Trillion
Q3 2025

A detailed history of Morgan Stanley transactions in Celcuity Inc. stock. As of the latest transaction made, Morgan Stanley holds 1,512,852 shares of CELC stock, worth $140 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,512,852

Previous 784,079 92.95%

Holding current value

$140 Million

Previous $10.5 Million 610.39%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$12.58 - $62.68 $9.17 Million - $45.7 Million	728,773 Added 92.95%	1,512,852 $74.4 Million
Q2 2025 Aug 15, 2025	SELL	$8.21 - $13.35 $434,054 - $705,801	-52,869 Reduced 6.32%	784,079 $10.5 Million
Q1 2025 May 15, 2025	SELL	$8.62 - $13.62 $344,308 - $544,023	-39,943 Reduced 4.56%	836,948 $8.46 Million
Q4 2024 Feb 14, 2025	SELL	$12.0 - $16.35 $6.19 Million - $8.43 Million	-515,814 Reduced 37.04%	876,891 $11.5 Million
Q3 2024 May 14, 2025	SELL	$13.98 - $19.15 $20.2 Million - $27.6 Million	-1,442,760 Reduced 50.88%	1,392,705 $20.8 Million
Q3 2024 Nov 14, 2024	SELL	$13.98 - $19.15 $20.2 Million - $27.6 Million	-1,442,760 Reduced 50.88%	1,392,705 $20.8 Million
Q2 2024 May 14, 2025	BUY	$14.1 - $20.78 $27.6 Million - $40.7 Million	1,958,574 Added 223.35%	2,835,465 $46.4 Million
Q2 2024 Oct 17, 2024	BUY	$14.1 - $20.78 $6.85 Million - $10.1 Million	486,120 Added 20.69%	2,835,465 $46.4 Million
Q2 2024 Aug 14, 2024	BUY	$14.1 - $20.78 $6.85 Million - $10.1 Million	486,120 Added 20.69%	2,835,465 $46.4 Million
Q1 2024 Oct 17, 2024	SELL	$13.74 - $21.6 $6.68 Million - $10.5 Million	-486,120 Reduced 17.14%	2,349,345 $50.7 Million
Q1 2024 Aug 16, 2024	BUY	$13.74 - $21.6 $2.12 Million - $3.33 Million	154,166 Added 7.02%	2,349,345 $50.7 Million
Q1 2024 May 15, 2024	BUY	$13.74 - $21.6 $2.12 Million - $3.33 Million	154,166 Added 7.02%	2,349,345 $50.7 Million
Q4 2023 Aug 16, 2024	SELL	$8.7 - $15.02 $5.57 Million - $9.62 Million	-640,286 Reduced 22.58%	2,195,179 $32 Million
Q4 2023 Feb 13, 2024	BUY	$8.7 - $15.02 $1.98 Million - $3.42 Million	227,403 Added 11.56%	2,195,179 $32 Million
Q3 2023 Nov 15, 2023	BUY	$8.96 - $10.75 $3.35 Million - $4.02 Million	374,196 Added 23.48%	1,967,776 $18 Million
Q2 2023 Aug 14, 2023	BUY	$9.39 - $12.18 $2.53 Million - $3.28 Million	269,067 Added 20.31%	1,593,580 $17.5 Million
Q1 2023 May 15, 2023	BUY	$9.4 - $12.82 $2.19 Million - $2.98 Million	232,672 Added 21.31%	1,324,513 $13.6 Million
Q4 2022 Feb 14, 2023	BUY	$7.55 - $14.01 $422,792 - $784,545	55,999 Added 5.41%	1,091,841 $15.3 Million
Q3 2022 Nov 14, 2022	BUY	$8.0 - $10.64 $6.18 Million - $8.21 Million	771,918 Added 292.48%	1,035,842 $10.4 Million
Q2 2022 Oct 27, 2022	BUY	$5.35 - $10.11 $1.31 Million - $2.47 Million	244,563 Added 1263.17%	263,924 $2.4 Million
Q2 2022 Aug 15, 2022	BUY	$5.35 - $10.11 $1.31 Million - $2.47 Million	244,563 Added 1263.17%	263,924 $2.4 Million
Q1 2022 Oct 27, 2022	SELL	$7.93 - $13.33 $1.94 Million - $3.26 Million	-244,563 Reduced 92.66%	19,361 $182,000
Q1 2022 May 13, 2022	BUY	$7.93 - $13.33 $50,712 - $85,245	6,395 Added 49.32%	19,361 $182,000
Q4 2021 Feb 14, 2022	BUY	$11.96 - $19.35 $16,468 - $26,644	1,377 Added 11.88%	12,966 $171,000
Q3 2021 Nov 15, 2021	BUY	$17.35 - $24.87 $201,069 - $288,218	11,589 New	11,589 $207,000

Others Institutions Holding CELC

# of Institutions

162

Shares Held

36M

Call Options Held

539K

Put Options Held

191K

View Full List

About Celcuity Inc.

Ticker CELC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 14,941,300
Market Cap $1.38B
Description
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therap...

More about CELC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account